New TB vaccine trial aims to shield millions
NCT ID NCT06732583
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new vaccine called Ad5-105K to see if it is safe and triggers an immune response against tuberculosis (TB). About 36 healthy adults aged 18 to 49 who have been exposed to TB bacteria (but have no active disease) will receive either the vaccine or a placebo. The main goal is to check for side effects and measure antibody levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LATENT TUBERCULOSIS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rumah Sakit Islam Jakarta Cempaka Putih
Jakarta, Indonesia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune profiling unlock the hidden stages of tuberculosis?
- Could inhaled TB drugs curb the spread of Drug-Resistant tuberculosis?
- Can new tests predict who will develop active TB?
- Could a 3-Month TB cocktail replace the standard 6-Month regimen?
- Could a simple blood test ensure the right TB dose for kids?
- Community-Driven TB screening aims to reach vulnerable immigrants